Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection

Molecules

Volumn 20, Issue 6, 2015, Pages 11154-11172

  Anaya Segura, Mónica Alejandra ^a   García Martínez, Froylan Arturo ^b   Montes Almanza, Luis Ángel ^b   Díaz, Benjamín Gómez ^c   Ávila Ramírez, Guillermina ^d   Alvarez Maya, Ikuri ^a   Coral Vázquez, Ramón Mauricio ^e   Mondragón Terán, Paul ^b   Escobar Cedillo, Rosa Elena ^c   García Calderón, Noemí ^f,g   Vázquez Cardenas, Norma Alejandra ^h   García, Silvia ^b   López Hernández, Luz Berenice ^b  

^a CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO   (Mexico)

^b National Medical Centre 20 de Noviembre Institute for Social Security of State Workers   (Mexico)

^c National Institute of Rehabilitation   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^f Asociación de Distrofia Muscular de Occidente A C   (Mexico)

^g INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^h UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

Author keywords

Biomarkers; Duchenne; FSTN; GDF 8; MMP 2; MMP 9; Monitoring; TIMP 1

Indexed keywords

BIOLOGICAL MARKER; SCLEROPROTEIN;

BLOOD; CASE CONTROL STUDY; CHILD; FEMALE; GENETICS; HETEROZYGOTE; HUMAN; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SKELETAL MUSCLE;

BIOMARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HETEROZYGOTE; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; SENSITIVITY AND SPECIFICITY;

EID: 84938369872     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200611154     Document Type: Article

References (54)

1. Bhattacharya, S.; Das, A.; Dasgupta, R.; Bagchi, A. Analyses of the presence of mutations in dystrophin protein to predict their relative influences in the onset of duchenne muscular dystrophy. Cell. Signal. 2014, 26, 2857-2864.
2. Van Westering, T.L.; Betts, C.A.; Wood, M.J. Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. Molecules 2015, 20, 8823-8855.
3. Piko, H.; Vancso, V.; Nagy, B.; Ban, Z.; Herczegfalvi, A.; Karcagi, V. Dystrophin gene analysis in hungarian duchenne/becker muscular dystrophy families-Detection of carrier status in symptomatic and asymptomatic female relatives. Neuromuscul. Disord. 2009, 19, 108-112.
4. Mercier, S.; Toutain, A.; Toussaint, A.; Raynaud, M.; de Barace, C.; Marcorelles, P.; Pasquier, L.; Blayau, M.; Espil, C.; Parent, P.; et al. Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age. Eur. J. Hum. Genet. 2013, 21, 855-863.
5. Ervasti, J.M.; Sonnemann, K.J. Biology of the striated muscle dystrophin-glycoprotein complex. Int. Rev. Cytol. 2008, 265, 191-225.
6. Nadarajah, V.D.; Van Putten, M.; Chaouch, A.; Garrood, P.; Straub, V.; Lochmuller, H.; Ginjaar, H.B.; Aartsma-Rus, A.M.; van Ommen, G.J.; den Dunnen, J.T.; et al. Serum matrix metalloproteinase-9 (mmp-9) as a biomarker for monitoring disease progression in duchenne muscular dystrophy (dmd). Neuromuscul. Disord. 2011, 21, 569-578.
7. Hurnaus, S.; Mueller-Felber, W.; Pongratz, D.; Schoser, B.G. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders. Eur. Neurol. 2006, 55, 204-208.
8. Hindi, S.M.; Shin, J.; Ogura, Y.; Li, H.; Kumar, A. Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice. PLoS ONE 2013, 8, e72121.
9. Bozzi, M.; Sciandra, F.; Brancaccio, A. Role of gelatinases in pathological and physiological processes involving the dystrophin-glycoprotein complex. J. Int. Soc. Matrix Biol. 2015, 44-46, 130-137.
10. Sbardella, D.; Sciandra, F.; Gioia, M.; Marini, S.; Gori, A.; Giardina, B.; Tarantino, U.; Coletta, M.; Brancaccio, A.; Bozzi, M. Alpha-dystroglycan is a potential target of matrix metalloproteinase mmp-2. J. Int. Soc. Matrix Biol. 2015, 41, 2-7.
11. Buchholz, B.; Perez, V.; Siachoque, N.; Miksztowicz, V.; Berg, G.; Rodriguez, M.; Donato, M.; Gelpi, R.J. Dystrophin proteolysis: A potential target for mmp-2 and its prevention by ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2014, 307, H88-H96.
12. Kherif, S.; Lafuma, C.; Dehaupas, M.; Lachkar, S.; Fournier, J.G.; Verdiere-Sahuque, M.; Fardeau, M.; Alameddine, H.S. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: A study in experimentally injured and mdx muscles. Dev. Biol. 1999, 205, 158-170.
13. Miyazaki, D.; Nakamura, A.; Fukushima, K.; Yoshida, K.; Takeda, S.; Ikeda, S. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum. Mol. Genet. 2011, 20, 1787-1799.
14. Shin, J.; Tajrishi, M.M.; Ogura, Y.; Kumar, A. Wasting mechanisms in muscular dystrophy. Int. J. Biochem. Cell Biol. 2013, 45, 2266-2279.
15. Zocevic, A.; Rouillon, J.; Wong, B.; Servais, L.; Voit, T.; Svinartchouk, F. Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in duchenne muscular dystrophy. Neuromuscul. Disord. 2015, 25, 444-446.
16. Allen, R.E.; Boxhorn, L.K. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J. Cell. Physiol. 1987, 133, 567-572.
17. Li, Y.; Foster, W.; Deasy, B.M.; Chan, Y.; Prisk, V.; Tang, Y.; Cummins, J.; Huard, J. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. Am. J. Pathol. 2004, 164, 1007-1019.
18. Ishitobi, M.; Haginoya, K.; Zhao, Y.; Ohnuma, A.; Minato, J.; Yanagisawa, T.; Tanabu, M.; Kikuchi, M.; Iinuma, K. Elevated plasma levels of transforming growth factor beta1 in patients with muscular dystrophy. Neuroreport 2000, 11, 4033-4035.
19. Bradley, L.; Yaworsky, P.J.; Walsh, F.S. Myostatin as a therapeutic target for musculoskeletal disease. Cell. Mol. Life Sci. 2008, 65, 2119-2124.
20. Murphy, K.T.; Ryall, J.G.; Snell, S.M.; Nair, L.; Koopman, R.; Krasney, P.A.; Ibebunjo, C.; Holden, K.S.; Loria, P.M.; Salatto, C.T.; et al. Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am. J. Pathol. 2010, 176, 2425-2434.
21. Ryan, N.J. Ataluren: First global approval. Drugs 2014, 74, 1709-1714.
22. Voit, T.; Topaloglu, H.; Straub, V.; Muntoni, F.; Deconinck, N.; Campion, G.; De Kimpe, S.J.; Eagle, M.; Guglieri, M.; Hood, S.; et al. Safety and efficacy of drisapersen for the treatment of duchenne muscular dystrophy (demand ii): An exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014, 13, 987-996.
23. Bushby, K.; Finkel, R.; Wong, B.; Barohn, R.; Campbell, C.; Comi, G.P.; Connolly, A.M.; Day, J.W.; Flanigan, K.M.; Goemans, N.; et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014, 50, 477-487.
24. Aartsma-Rus, A.; Ferlini, A.; Vroom, E. Biomarkers and surrogate endpoints in duchenne: Meeting report. Neuromuscul. Disord. 2014, 24, 743-745.
25. Ayoglu, B.; Chaouch, A.; Lochmuller, H.; Politano, L.; Bertini, E.; Spitali, P.; Hiller, M.; Niks, E.H.; Gualandi, F.; Ponten, F.; et al. Affinity proteomics within rare diseases: A bio-nmd study for blood biomarkers of muscular dystrophies. EMBO Mol. Med. 2014, 6, 918-936.
26. Hashim, R.; Shaheen, S.; Ahmad, S.; Sattar, A.; Khan, F.A. Comparison of serum creatine kinase estimation with short tandem repeats based linkage analysis in carriers and affected children of duchenne muscular dystrophy. J. Ayub Med. Coll. Abbottabad 2011, 23, 125-128.
27. Rouillon, J.; Zocevic, A.; Leger, T.; Garcia, C.; Camadro, J.M.; Udd, B.; Wong, B.; Servais, L.; Voit, T.; Svinartchouk, F. Proteomics profiling of urine reveals specific titin fragments as biomarkers of duchenne muscular dystrophy. Neuromuscul. Disord. 2014, 24, 563-573.
28. McPherron, A.C.; Lawler, A.M.; Lee, S.J. Regulation of skeletal muscle mass in mice by a new tgf-beta superfamily member. Nature 1997, 387, 83-90.
29. McPherron, A.C.; Lee, S.J. Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. USA 1997, 94, 12457-12461.
30. Abe, S.; Soejima, M.; Iwanuma, O.; Saka, H.; Matsunaga, S.; Sakiyama, K.; Ide, Y. Expression of myostatin and follistatin in mdx mice, an animal model for muscular dystrophy. Zool. Sci. 2009, 26, 315-320.
31. Fukushima, K.; Nakamura, A.; Ueda, H.; Yuasa, K.; Yoshida, K.; Takeda, S.; Ikeda, S. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (cxmdj). BMC Musculoskelet. Disord. 2007, 8, doi:10.1186/1471-2474-8-54.
32. Gomez, D.E.; Alonso, D.F.; Yoshiji, H.; Thorgeirsson, U.P. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74, 111-122.
33. Kolkenbrock, H.; Orgel, D.; Hecker-Kia, A.; Zimmermann, J.; Ulbrich, N. Generation and activity of the ternary gelatinase b/timp-1/lmw-stromelysin-1 complex. Biol. Chem. Hoppe Seyler 1995, 376, 495-500.
34. Borden, P.; Heller, R.A. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit. Rev. Eukaryot. Gene Expr. 1997, 7, 159-178.
35. Cynthia Martin, F.; Hiller, M.; Spitali, P.; Oonk, S.; Dalebout, H.; Palmblad, M.; Chaouch, A.; Guglieri, M.; Straub, V.; Lochmuller, H.; et al. Fibronectin is a serum biomarker for duchenne muscular dystrophy. Proteomics Clin. Appl. 2014, 8, 269-278.
36. Hu, J.; Kong, M.; Ye, Y.; Hong, S.; Cheng, L.; Jiang, L. Serum mir-206 and other muscle-specific micrornas as non-invasive biomarkers for duchenne muscular dystrophy. J. Neurochem. 2014, 129, 877-883.
37. Cacchiarelli, D.; Legnini, I.; Martone, J.; Cazzella, V.; D'Amico, A.; Bertini, E.; Bozzoni, I. Mirnas as serum biomarkers for duchenne muscular dystrophy. EMBO Mol. Med. 2011, 3, 258-265.
38. Sun, G.; Haginoya, K.; Chiba, Y.; Uematsu, M.; Hino-Fukuyo, N.; Tanaka, S.; Onuma, A.; Iinuma, K.; Tsuchiya, S. Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy. J. Neurol. Sci. 2010, 297, 19-28.
39. Brunherotti, M.A.; Sobreira, C.; Rodrigues-Junior, A.L.; de Assis, M.R.; Terra Filho, J.; Baddini Martinez, J.A. Correlations of egen klassifikation and barthel index scores with pulmonary function parameters in duchenne muscular dystrophy. Heart Lung J. Crit. Care 2007, 36, 132-139.
40. Rodino-Klapac, L.R.; Janssen, P.M.; Shontz, K.M.; Canan, B.; Montgomery, C.L.; Griffin, D.; Heller, K.; Schmelzer, L.; Handy, C.; Clark, K.R.; et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged dmd model. Hum. Mol. Genet. 2013, 22, 4929-4937.
41. Camerino, G.M.; Cannone, M.; Giustino, A.; Massari, A.M.; Capogrosso, R.F.; Cozzoli, A.; De Luca, A. Gene expression in mdx mouse muscle in relation to age and exercise: Aberrant mechanical-metabolic coupling and implications for pre-clinical studies in duchenne muscular dystrophy. Hum. Mol. Genet. 2014, 23, 5720-5732.
42. Awano, H.; Takeshima, Y.; Okizuka, Y.; Saiki, K.; Yagi, M.; Matsuo, M. Wide ranges of serum myostatin concentrations in duchenne muscular dystrophy patients. Clin. Chim. Acta 2008, 391, 115-117.
43. Chien, Y.H.; Han, D.S.; Hwu, W.L.; Thurberg, B.L.; Yang, W.S. Myostatin and insulin-like growth factor i: Potential therapeutic biomarkers for pompe disease. PLoS ONE 2013, 8, e71900.
44. Hansen, J.; Brandt, C.; Nielsen, A.R.; Hojman, P.; Whitham, M.; Febbraio, M.A.; Pedersen, B.K.; Plomgaard, P. Exercise induces a marked increase in plasma follistatin: Evidence that follistatin is a contraction-induced hepatokine. Endocrinology 2011, 152, 164-171.
45. Ma, K.; Mallidis, C.; Artaza, J.; Taylor, W.; Gonzalez-Cadavid, N.; Bhasin, S. Characterization of 5′-regulatory region of human myostatin gene: Regulation by dexamethasone in vitro. Am. J. Physiol. Endocrinol. Metab. 2001, 281, E1128-E1136.
46. Qin, J.; Du, R.; Yang, Y.Q.; Zhang, H.Q.; Li, Q.; Liu, L.; Guan, H.; Hou, J.; An, X.R. Dexamethasone-induced skeletal muscle atrophy was associated with upregulation of myostatin promoter activity. Res. Vet. Sci. 2013, 94, 84-89.
47. Miyamoto, T.; Carrero, J.J.; Qureshi, A.R.; Anderstam, B.; Heimburger, O.; Barany, P.; Lindholm, B.; Stenvinkel, P. Circulating follistatin in patients with chronic kidney disease: Implications for muscle strength, bone mineral density, inflammation, and survival. Clin. J. Am. Soc. Nephrol. 2011, 6, 1001-1008.
48. Mathews, K.D.; Cunniff, C.; Kantamneni, J.R.; Ciafaloni, E.; Miller, T.; Matthews, D.; Cwik, V.; Druschel, C.; Miller, L.; Meaney, F.J.; et al. Muscular dystrophy surveillance tracking and research network (md starnet): Case definition in surveillance for childhood-onset duchenne/becker muscular dystrophy. J. Child. Neurol. 2010, 25, 1098-1102.
49. Vazquez-Cardenas, N.A.; Ibarra-Hernandez, F.; Lopez-Hernandez, L.B.; Escobar-Cedillo, R.E.; Ruano-Calderon, L.A.; Gomez-Diaz, B.; Garcia-Calderon, N.; Carriedo-Davila, M.F.; Rojas-Hurtado, L.G.; Luna-Padron, E.; et al. Diagnosis and treatment with steroids for patients with duchenne muscular dystrophy: Experience and recommendations for Mexico. Rev. Neurol. 2013, 57, 455-462.
50. Bushby, K.; Finkel, R.; Birnkrant, D.J.; Case, L.E.; Clemens, P.R.; Cripe, L.; Kaul, A.; Kinnett, K.; McDonald, C.; Pandya, S.; et al. Diagnosis and management of duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet. Neurol. 2010, 9, 77-93.
51. Gustincich, S.; Manfioletti, G.; Del Sal, G.; Schneider, C.; Carninci, P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 1991, 11, 298-300, 302.
52. Lopez-Hernandez, L.B.; Gomez-Diaz, B.; Luna-Angulo, A.B.; Anaya-Segura, M.; Bunyan, D.J.; Zuniga-Guzman, C.; Escobar-Cedillo, R.E.; Roque-Ramirez, B.; Ruano-Calderon, L.A.; Rangel-Villalobos, H.; et al. Comparison of mutation profiles in the duchenne muscular dystrophy gene among populations: Implications for potential molecular therapies. Int. J. Mol. Sci. 2015, 16, 5334-5346.
53. Gomez-Diaz, B.; Rosas-Vargas, H.; Roque-Ramirez, B.; Meza-Espinoza, P.; Ruano-Calderon, L.A.; Fernandez-Valverde, F.; Escalante-Bautista, D.; Escobar-Cedillo, R.E.; Sanchez-Chapul, L.; Vargas-Canas, S.; et al. Immunodetection analysis of muscular dystrophies in Mexico. Muscle Nerve 2012, 45, 338-345.
54. Janssen, B.; Hartmann, C.; Scholz, V.; Jauch, A.; Zschocke, J. Mlpa analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: Potential and pitfalls. Neurogenetics 2005, 6, 29-35.